ArticleAnnals of clinical and translational neurology2014
Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis.
Article in Annals of clinical and translational neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 53 citations in OpenAlex.
- Targeting IL-33 in Precision Neuroimmunology: Cellular Mechanisms and Therapeutic Strategies for CNS Disorders.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Review
- Decitabine co-operates with the IL-33/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma.Journal of experimental & clinical cancer research : CR · 2025Article
- ST2 levels and neurodegenerative diseases: is this a significant relation?Annals of medicine and surgery (2012) · 2024Review
- Activator protein transcription factors coordinate human IL-33 expression from noncanonical promoters in chronic airway disease.JCI insight · 2024Article
- Butyrate inhibitsFrontiers in immunology · 2023Article
- Mast Cell Cytokines in Acute and Chronic Gingival Tissue Inflammation: Role of IL-33 and IL-37.International journal of molecular sciences · 2022Review
- Review
- Role of Ketogenic Diets in Multiple Sclerosis and Related Animal Models: An Updated Review.Advances in nutrition (Bethesda, Md.) · 2022Review
- IL-33 genetics and epigenetics in immune-related diseases.Clinical and molecular allergy : CMA · 2021Article
- Role of the IL-33/ST2 receptor axis in ovarian cancer progression.Oncology letters · 2021Review
- IL-33 Is Involved in the Anti-Inflammatory Effects of Butyrate and Propionate on TNFα-Activated Endothelial Cells.International journal of molecular sciences · 2021Article
- Therapeutic Opportunities of Interleukin-33 in the Central Nervous System.Frontiers in immunology · 2021Review
- Longitudinal assessment and stability of long non-coding RNA gene expression profiles measured in human peripheral whole blood collected into PAXgene blood RNA tubes.BMC research notes · 2020Article
- The Role of IL-33/ST2 Pathway in Tumorigenesis.International journal of molecular sciences · 2018Review
- Why monkeys do not get multiple sclerosis (spontaneously): An evolutionary approach.Evolution, medicine, and public health · 2018Review
- Critical Roles of IL-33/ST2 Pathway in Neurological Disorders.Mediators of inflammation · 2018Review
- Longitudinal changes in the expression of IL-33 and IL-33 regulated genes in relapsing remitting MS.PloS one · 2018Article
- Expression and Function of IL-33/ST2 Axis in the Central Nervous System Under Normal and Diseased Conditions.Frontiers in immunology · 2018Review
- M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection.Scientific reports · 2017Article
- Epithelial Cell Regulation of Allergic Diseases.Current allergy and asthma reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
We examined the expression of IL-33 as an indicator of an innate immune response in relapsing remitting MS (RRMS) and controls. Based on our previous studies we proposed a link between the expression of IL-33 and IL-33 regulated genes to histone deacetylase (HDAC) activity and in particular HDAC3, an enzyme that plays a role in the epigenetic regulation of a number of genes including those which regulate inflammation. Our studies showed that intracellular expressions of IL-33 and IL-33 regulated genes are increased in patients with RRMS. In addition, following
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.